Free Trial
→ “Fed Proof” Your Bank Account with THESE 4 Simple Steps (From Weiss Ratings) (Ad)

111 Q1 2023 Earnings Report

111 logo
$8.36 +0.16 (+1.95%)
As of 02/21/2025 03:59 PM Eastern
Earnings HistoryForecast

111 EPS Results

Actual EPS
-$0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$538.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q1 2023
Date
6/15/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

111 Earnings Headlines

111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow
February 20 at 5:00 AM | prnewswire.com
Weiss Ratings Reiterates "Sell (E+)" Rating for 111 (NASDAQ:YI)
February 20 at 3:11 AM | americanbankingnews.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
Short Interest in 111, Inc. (NASDAQ:YI) Increases By 66.9%
February 13, 2025 | americanbankingnews.com
111, Inc. meets NASDAQ's listing standards again
February 11, 2025 | msn.com
111 Inc regains Nasdaq compliance with share price
February 11, 2025 | msn.com
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles